Giuseppe Derosa^{1, 2,}, Angela D’Angelo^{1, 3}, Pamela Maffioli^{1, 4}

The aim of this study was to evaluate if a nutraceutical containing quercetin, rutin, bromelain and L-carnosine (Uricemin®) can reduce uric acid levels in subjects with values between ≥ 6 and < 7 mg/dl after 3 months of therapy. Patients were randomized to Uricemin® or placebo for three months. We evaluated body weight, fasting plasma glucose (FPG), lipid profile, uricemia (UA), high-sensitivity C-reactive protein (Hs-CRP) at baseline and after 3 months since the study start. Treatment tolerability was assessed evaluating transaminases, and creatinine, and all adverse events were recorded. A total of 116 patients were enrolled in the trial. Of these, 59 were randomized to the nutraceutical and 57 to placebo. One hundred and seven subjects completed the study, and were included in the analysis. We did not record any change in glycemia, or lipid profile in neither group. We observed a reduction of uricemia, and Hs-CRP in the group treated with Uricemin®, compared to baseline and to placebo (p < 0.05 for both). The results of this study suggested that a combination of quercetin, rutin, bromelain and L-carnosine can be useful in reducing uricemia in patients with borderline uricemia.

bromelain, hyperuricemia, L-carnosine, quercetin, rutin